TABLE OF CONTENTS
1 INTRODUCTION 12
1.1 OBJECTIVES OF THE STUDY 12
1.2 MARKET DEFINITION 12
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA IMPLANTABLE PORTS MARKET 12
1.4 CURRENCY AND PRICING 13
1.5 LIMITATIONS 13
1.6 MARKETS COVERED 13
2 MARKET SEGMENTATION 15
2.1 MARKETS COVERED 15
2.2 GEOGRAPHICAL SCOPE 16
2.3 YEARS CONSIDERED FOR THE STUDY 17
2.4 DBMR TRIPOD DATA VALIDATION MODEL 18
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 21
2.6 MULTIVARIATE MODELLING 22
2.7 TYPE SEGMENT LIFELINE CURVE 22
2.8 MARKET END USERS COVERAGE GRID 23
2.9 DBMR MARKET POSITION GRID 24
2.10 VENDOR SHARE ANALYSIS 25
2.11 SECONDARY SOURCES 26
2.12 ASSUMPTIONS 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 29
4.1 CONSUMER BUYING BEHAVIOUR 30
4.2 FACTORS AFFECTING BUYING DECISION 30
4.3 PRODUCT ADOPTION SCENARIO 30
4.4 REGULATION COVERAGE 31
4.5 BRAND ANALYSIS 33
4.6 RAW MATERIAL SOURCING ANALYSIS 34
4.7 IMPORT EXPORT SCENARIO 34
4.8 PORTER'S 5 FORCES 36
5 SUPPLY CHAIN ANALYSIS 37
5.1 LOGISTIC COSTS SCENARIO 37
5.2 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS 37
6 MARKET OVERVIEW 39
6.1 DRIVERS 41
6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES 41
6.1.2 GROWING DEMAND FOR MINIMALLY INVASIVE PROCEDURES 41
6.1.3 INCREASING ONCOLOGY AND CHEMOTHERAPY PROCEDURES 42
6.1.4 IMPROVED DEVICE DESIGN AND FUNCTIONALITY 42
6.2 RESTRAINTS 43
6.2.1 RISK OF INFECTIONS AND MECHANICAL COMPLICATIONS 43
6.2.2 STRINGENT REGULATORY REQUIREMENTS FOR APPROVAL PROCESS 43
6.3 OPPORTUNITIES 44
6.3.1 RISING DEMAND FOR IMPLANTABLE PORT DEVICES DUE TO HIGH SUCCESS RATE 44
6.3.2 EXPANSION OF HOME-BASED HEALTHCARE 44
6.4 CHALLENGES 45
6.4.1 LACK OF SKILLED PROFESSIONALS OR EXPERTISE 45
6.4.2 PRODUCT RECALL OF IMPLANTABLE PORT DEVICES 45
7 MIDDLE EAST & AFRICA IMPLANTABLE PORTS MARKET, BY TYPE 47
7.1 OVERVIEW 48
7.2 SINGLE LUMEN 51
7.3 DOUBLE LUMEN 51
7.4 POWER- INJECTABLE 52
8 MIDDLE EAST & AFRICA IMPLANTABLE PORTS MARKET, BY MATERIAL 53
8.1 OVERVIEW 54
8.2 POLYURETHANE 57
8.3 SILICONE 57
8.4 TITANIUM 58
8.5 OTHERS 59
9 MIDDLE EAST & AFRICA IMPLANTABLE PORTS MARKET, BY APPLICATION 60
9.1 OVERVIEW 61
9.2 CHEMOTHERAPY 64
9.3 BLOOD TRANSFUSION 64
9.4 ANTIBIOTICS 65
9.5 INTRAVENOUS INFUSION OF BLOOD PRODUCT 66
9.6 PAIN MANAGEMENT 66
9.7 OTHERS 67
10 MIDDLE EAST & AFRICA IMPLANTABLE PORTS MARKET, BY END USERS 68
10.1 OVERVIEW 69
10.2 HOSPITALS 72
10.3 CLINICS 72
10.4 AMBULATORY SURGICAL CENTER 73
10.5 DIALYSIS CENTER 73
10.6 OTHERS 75
11 MIDDLE EAST & AFRICA IMPLANTABLE PORTS MARKET, BY REGION 76
11.1 MIDDLE EAST & AFRICA 77
11.1.1 SAUDI ARABIA 83
11.1.2 SOUTH AFRICA 85
11.1.3 U.A.E 87
11.1.4 EGYPT 89
11.1.5 ISRAEL 91
11.1.6 REST OF MIDDLE EAST & AFRICA 93
12 MIDDLE EAST & AFRICA IMPLANTABLE PORTS MARKET: COMPANY LANDSCAPE 94
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 94
13 SWOT 95
14 MIDDLE EAST & AFRICA IMPLANTABLE PORTS MARKET, COMPANY PROFILE 96
14.1 B.BRAUN SE 96
14.1.1 COMPANY SNAPSHOT 96
14.1.2 COMPANY SHARE ANALYSIS 96
14.1.3 PRODUCT PORTFOLIO 97
14.1.4 RECENT DEVELOPMENTS 97
14.2 ANGIODYNAMICS 98
14.2.1 COMPANY SNAPSHOT 98
14.2.2 REVENUE ANALYSIS 98
14.2.3 COMPANY SHARE ANALYSIS 99
14.2.4 PRODUCT PORTFOLIO 99
14.2.5 RECENT DEVELOPMENT 99
14.3 BD 100
14.3.1 COMPANY SNAPSHOT 100
14.3.2 REVENUE ANALYSIS 100
14.3.3 COMPANY SHARE ANALYSIS 101
14.3.4 PRODUCT PORTFOLIO 101
14.3.5 RECENT DEVELOPMENT 101
14.4 TELEFLEX INCORPORATED 102
14.4.1 COMPANY SNAPSHOT 102
14.4.2 REVENUE ANALYSIS 102
14.4.3 COMPANY SHARE ANALYSIS 103
14.4.4 PRODUCT PORTFOLIO 103
14.4.5 RECENT DEVELOPMENTS 103
14.5 VYGON 104
14.5.1 COMPANY SNAPSHOT 104
14.5.2 COMPANY SHARE ANALYSIS 104
14.5.3 PRODUCT PORTFOLIO 105
14.5.4 RECENT DEVELOPMENT 105
14.6 AMI GMBH 106
14.6.1 COMPANY SNAPSHOT 106
14.6.2 PRODUCT PORTFOLIO 106
14.6.3 RECENT DEVELOPMENT 106
14.7 DISTRICLASS MDICAL 107
14.7.1 COMPANY SNAPSHOT 107
14.7.2 PRODUCT PORTFOLIO 107
14.7.3 RECENT DEVELOPMENT 107
14.8 ICU MEDICAL, INC. 108
14.8.1 COMPANY SNAPSHOT 108
14.8.2 REVENUE ANALYSIS 108
14.8.3 PRODUCT PORTFOLIO 109
14.8.4 RECENT DEVELOPMENT 109
14.9 PAKUMEDMEDICAL PRODUCTS GMBH 110
14.9.1 COMPANY SNAPSHOT 110
14.9.2 PRODUCT PORTFOLIO 110
14.9.3 RECENT DEVELOPMENTS 110
15 QUESTIONNAIRE 111
16 RELATED REPORTS 114

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.